The ASX stocks hoping to profit from endless search for an ‘elixir of youth’

Time hasn’t wearied the anti-ageing industry, which is tipped to be worth $US110 billion by 2033. These ASX stocks are grabbing a piece of the action.

The quest to stay looking younger for longer has become big business. Picture: Getty Images

Humans for centuries have hunted for the elusive “elixir of youth”.

This pursuit, and a stream of scientific developments, have led to a thriving industry, with ASX companies playing a significant role.

While some turn to traditional and herbal remedies passed down through generations, others look to modern advancements, investing in skincare, cosmetic procedures, and wellness regimes in the hope of anti-ageing benefits.

The desire to maintain youthful skin, reduce wrinkles, and combat the signs of ageing, is generating high demand.

---

For the latest health news, sign up here for free Stockhead daily newsletters

---

A CAGR of 5.5 per cent between the years 2023 and 2033 is forecast for anti-ageing products, services, and devices.

Future Market Insights (FMI) anticipates substantial revenue growth in the global anti-ageing market, with forecasts suggesting an increase from $US64 billion this year to a staggering $US109.8 billion by 2033.

ASX companies are in the thick of it, working to help us stay more youthful and, in the process, benefit from rising demand for anti-ageing products and services.

BIOXYNE (ASX:BXN)

Life sciences and health products company BXN is the parent company of Breathe Life Sciences Group, a leading sponsor of medicinal cannabis in Australia supplying cultivators, manufacturers, pharmacies and patients nationwide.

The Breathe Life Sciences Group (BLS), which includes the trademarked Dr Watson brand, was acquired by BXN in May 2023 and is a 100 per cent wholly owned subsidiary.

Director of sales for beauty and skincare Stephanie Cowan told Stockhead BLS has focused on developing skincare that works for every skin type, really putting a spotlight on healthier anti-ageing solutions.

“We wanted people to feel confident in their skin and care more about the health of it rather than focusing on social media pressures around beauty standards,” Cowan says

“We’ve teamed up with large high street brands to help them create unique CBD products as well as offer a wide range of white label products with a high level of CBD to ensure fast, effective results for all skin types.”

Cowan says CBD is a game-changer for ageing skin – hydrating, reducing inflammation, and combating oxidative stress.

“The multifunctional approach of CBD contributes not only to a healthier complexion but also to a more resilient and youthful appearance over time – it’s like a one-stop-shop for a healthier and more youthful glow,” she says.

Cowan says their top selling product for anti-ageing is the High Strength Balm, with 1.5 per cent CBD, combined with niacinamide.

“It’s an effective anti-inflammatory cream, many users report experiencing overnight benefits for issues like spots and skin irritation," she says.

---

MORE FROM STOCKHEAD: Cannabis boom ‘when, not if’ | Imugene war on cancer steps up | ASX biotech winners for November

---

ANAGENICS (ASX:AN1)

AN1 is a beauty, health and wellness company specialising in a diverse array of clinically proven anti-ageing beauty and wellness solutions, either developed internally or curated from global brands.

Managing director and CEO Scott Greasley told Stockhead that operating through its wholly-owned subsidiary BLC Cosmetics Pty Ltd, AN1 was dedicated to the development, production, and global marketing of anti-ageing products.

“Our premier anti-ageing hair care line, marketed under the name évolis, boasts a strong presence in key markets such as Australia, Japan, the US, and China,” he says.

Greasley says évolis harnesses the company’s unique, patented, plant based FGF5 inhibitor technology to improve hair growth and quality, while preventing hair loss.

Furthermore, BLC Cosmetics serves as a distributor for a variety of esteemed local and international skincare and wellness brands.

Its flagship anti-ageing brands include:

• Hydropeptide, harnessing unique peptide-driven epigenetic anti-ageing technology
• Priori, with its proprietary DNA repair enzyme complex
• Thalgo, a prestige spa brand that leans into the French spa tradition, while targeting skin concerns at various ages with proven actives sourced from the sea.

EZZ LIFE SCIENCE (ASX:EZZ)

EZZ is focusing its genomic research and product development to isolate and unpack four key areas including:

• Genetic longevity
• Human papillomavirus (some 80 per cent of sexually active adults have it)
• Children’s health weight management

EZZ offers health supplements, health food and probiotics as well as skincare products under two brands, EZZ and EAORON respectively.

The company’s products are sold nationally as well as in New Zealand, Singapore, China and Southeast Asia. China has become a particularly important market for EZZ, which has a strong e-commerce presence in the country.

EZZ reported strong FY23 results including revenue growth of 147.3 per cent year on year to $37.1 million.

There was also a significant expansion in gross margins to 76.8 per cent from 50.0 per cent in the previous year, which resulted in EBITDA of $4.8 million, a sharp increase of 172.5 per cent from FY22.

---

Visit Stockhead, where ASX small caps are big deals

---

EZZ chairman Glenn Cross said longevity and anti-ageing were proving particularly important for the company.

“The anti-ageing market is experiencing exponential growth, driven by an ageing global population increasingly cognisant of the benefits of cutting-edge treatments and technologies,” he says.

He says EZZ is at the forefront of this burgeoning market leveraging advanced research collaborations, notably with the Auckland University of Technology, to explore the potential of nicotinamide mononucleotide (NMN) and nicotinamide adenine dinucleotide (NAD+).

“These compounds, found in every cell of our body, play a vital role in cellular energy production and DNA repair,” Cross says.

“They are instrumental in cellular energy production and DNA repair, offering promising avenues for enhancing cellular energy, promoting DNA integrity, regulating metabolic functions, and potentially providing neuroprotection.

“EZZ recognises the profound impact of these breakthroughs and is strategically positioning itself to harness their significant potential.”

Currently the TGA has not approved any NMN products for domestic consumption within Australia as a food additive with Australian consumers currently only able to legally purchase limited quantities of NMN from overseas under the Personal Importation Scheme.

The TGA has approved EZZ’s NMN 500,000 for export only and the primary export market for this product is currently mainland China.

A number of NAD+ supplements have been approved for domestic consumption by the TGA, including EZZ’s Daily Energy & Wellbeing, which contains NAD+.

“The global shift towards increased information availability has played a pivotal role in the rising awareness of the benefits associated with anti-ageing treatments.

“EZZ acknowledges this trend and is committed to developing products that align with consumer preferences, drawing inspiration from cutting-edge research in the rapidly evolving field of anti-ageing.

“As the company embraces the rapid developments in anti-ageing research, EZZ is poised to not only meet but exceed consumer expectations with innovative and scientifically-backed products.”

This content first appeared on stockhead.com.au

At Stockhead, we tell it like it is. While Bioxyne and EZZ Life Science are Stockhead advertisers, they did not sponsor this article.

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox. Click here